The Advisory Committee on Immunization Practices’ Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
Author
Wallace, M.Moulia, D.
Moulia, D.
Ricketts, E.K.
Minhaj, F.S.
Link-Gelles, R.
Curran, K.G.
Hadler, S.C.
Asif, A.
Godfrey, M.
Hall, E.
Fiore, A.
Meyer, S.
Su, J.R.
Weintraub, E.
Oster, M.E.
Shimabukuro, T.T.
Campos-Outcalt, D.
Morgan, R.L.
Bell, B.P.
Brooks, O.
Talbot, H.K.
Lee, G.M.
Daley, M.F.
Oliver, S.E.
Affiliation
College of Medicine, University of ArizonaIssue Date
2022
Metadata
Show full item recordCitation
Wallace, M., Moulia, D., Moulia, D., Ricketts, E. K., Minhaj, F. S., Link-Gelles, R., Curran, K. G., Hadler, S. C., Asif, A., Godfrey, M., Hall, E., Fiore, A., Meyer, S., Su, J. R., Weintraub, E., Oster, M. E., Shimabukuro, T. T., Campos-Outcalt, D., Morgan, R. L., … Oliver, S. E. (2022). The Advisory Committee on Immunization Practices’ Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines—United States, February 2022. MMWR Recommendations and Reports.Journal
MMWR Recommendations and ReportsRights
All material in the MMWR series is in the public domain and may be used and reprinted without special permission.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA), and the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use among persons aged ≥18 years (1), which was adopted by CDC. During December 19, 2020–January 30, 2022, approximately 204 million doses of Moderna COVID-19 vaccine were administered in the United States (2) as a primary series of 2 intramuscular doses (100 μg [0.5 mL] each) 4 weeks apart. On January 31, 2022, FDA approved a Biologics License Application (BLA) for use of the Moderna COVID-19 vaccine (Spikevax, ModernaTX, Inc.) in persons aged ≥18 years (3). On February 4, 2022, the ACIP COVID-19 Vaccines Work Group conclusions regarding recommendations for the use of the Moderna COVID-19 vaccine were presented to ACIP at a public meeting. The Work Group’s deliberations were based on the Evidence to Recommendation (EtR) Framework,* which incorporates the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach† to rank evidence quality. In addition to initial clinical trial data, ACIP considered new information gathered in the 12 months since issuance of the interim recommendations, including additional follow-up time in the clinical trial, real-world vaccine effectiveness studies, and postauthorization vaccine safety monitoring. ACIP also considered comparisons of mRNA vaccine effectiveness and safety in real-world settings when first doses were administered 8 weeks apart instead of the original intervals used in clinical trials (3 weeks for BNT162b2 [Pfizer-BioNTech] COVID-19 vaccine and 4 weeks for Moderna COVID-19 vaccine). Based on this evidence, CDC has provided guidance that an 8-week interval might be optimal for some adolescents and adults. The additional information gathered since the issuance of the interim recommendations increased certainty that the benefits of preventing symptomatic and asymptomatic SARS-CoV-2 infection, hospitalization, and death outweigh vaccine-associated risks of the Moderna COVID-19 vaccine. On February 4, 2022, ACIP modified its interim recommendation to a standard recommendation§ for use of the fully licensed Moderna COVID-19 vaccine in persons aged ≥18 years. © 2020, Ugeskrift for Laeger. All Rights Reserved.Note
Public domain journalISSN
1057-5987PubMed ID
35298454Version
Final published versionae974a485f413a2113503eed53cd6c53
10.15585/mmwr.mm7111a4
Scopus Count
Collections
Except where otherwise noted, this item's license is described as All material in the MMWR series is in the public domain and may be used and reprinted without special permission.
Related articles
- Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021.
- Authors: Dooling K, Gargano JW, Moulia D, Wallace M, Rosenblum HG, Blain AE, Hadler SC, Plumb ID, Moline H, Gerstein J, Collins JP, Godfrey M, Campos-Outcalt D, Morgan RL, Brooks O, Talbot HK, Lee GM, Daley MF, Oliver SE
- Issue date: 2021 Sep 24
- The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021.
- Authors: Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, Chamberland M, Campos-Outcalt D, Morgan RL, Brooks O, Talbot HK, Lee GM, Bell BP, Daley MF, Mbaeyi S, Dooling K, Oliver SE
- Issue date: 2021 Nov 12
- The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.
- Authors: Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K
- Issue date: 2021 Jan 1
- The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.
- Authors: Wallace M, Woodworth KR, Gargano JW, Scobie HM, Blain AE, Moulia D, Chamberland M, Reisman N, Hadler SC, MacNeil JR, Campos-Outcalt D, Morgan RL, Daley MF, Romero JR, Talbot HK, Lee GM, Bell BP, Oliver SE
- Issue date: 2021 May 21
- The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
- Authors: Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K
- Issue date: 2020 Dec 18